Astrazeneca
Entity.
- Evidence
- 77 documents · 31 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 28 Apr 2026, last seen 3 Nov 2026
- Measured
- 4% of mentions say something specific about it; the rest only name it
- As of
- 4 Nov 2026
Where this comes from
- BioPharma Dive · 2026-11-02 · Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience (opens the source in a new tab)
- MarketBeat · 2026-10-31 · AstraZeneca (NYSE:AZN) Stock Rating Upgraded by Wall Street Zen (opens the source in a new tab)
- STAT News · 2026-10-30 · STAT+: Pharmalittle: We’re reading about AstraZeneca cost-cutting, Sun Pharma facility problems, and more (opens the source in a new tab)
- City A.M. · 2026-10-30 · Astrazeneca shares jump as it kicks off $2bn drug pipeline investment (opens the source in a new tab)
- European Medical Journal · 2026-10-30 · AstraZeneca targets $1.5bn annual savings to support pipeline (opens the source in a new tab)
- Euronews · 2026-10-30 · AstraZeneca profit jumps 23% on cancer drugs as it unveils major savings plan (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-30 · AstraZeneca cans late-stage Ultomiris trial on lacklustre efficacy predictions (opens the source in a new tab)
- MarketBeat · 2026-10-28 · Erste Group Bank Lowers Earnings Estimates for AstraZeneca (opens the source in a new tab)
- Endpoints News · 2026-10-28 · AstraZeneca’s bruising summer raises the stakes for 2027 (opens the source in a new tab)
- Bioxconomy · 2026-10-26 · AstraZeneca to use Oracle AI to speed trial recruitment (opens the source in a new tab)